Cargando…
Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
Melanoma is a disease process which has been increasing in incidence over the past three decades and metastatic melanoma carries a poor prognosis. Through genetic studies of this disease, it has been determined that the BRAF V600 mutation plays a major role in the pathophysiology of the disease and...
Autores principales: | Swofford, Brenen P., Homsi, Jade |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664253/ https://www.ncbi.nlm.nih.gov/pubmed/29181212 http://dx.doi.org/10.1155/2017/8241624 |
Ejemplares similares
-
Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
por: Swofford, Brenen P., et al.
Publicado: (2017) -
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021) -
Sigmoid Adenocarcinoma with Regional Scrotal Metastasis
por: Swofford, Brenen P., et al.
Publicado: (2017) -
SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy
por: Chew, Sonya Minmin, et al.
Publicado: (2021) -
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
por: White, Michael G., et al.
Publicado: (2021)